Gyre.O
Gyre Therapeutics Inc operates as a biotechnology company within the Health Care sector, generating revenue through its disclosed business activities.
Business. Gyre Therapeutics Inc operates as a biotechnology company within the Health Care sector, generating revenue through its disclosed business activities.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Gyre Therapeutics Inc operates as a biotechnology company within the Health Care sector, generating revenue through its disclosed business activities.
The company maintains a conservative capital structure with zero debt-to-equity and total liabilities of $23.85 million against total equity of $106.03 million. Liquidity is supported by cash and equivalents of $37.07 million, which exceeds total liabilities, resulting in a low liquidity risk assessment. The balance sheet reflects a net asset position that underpins the current valuation metrics.
Profitability metrics show a net income of $9.88 million on revenue of $116.59 million, indicating a positive operating margin. However, return on equity is reported as -0.06 and return on assets as -0.0383, suggesting discrepancies between accounting net income and the computed return ratios or the inclusion of non-cash items in the equity base. The negative EV/EBITDA of -3616.32 indicates that EBITDA is likely negative or near zero, contrasting with the positive operating income of $11.49 million.
Segment and geographic data are not provided in the available source documents, preventing an analysis of revenue concentration or regional exposure. The company's revenue mix remains undifferentiated in the current dataset.
Historical period data for revenue and net income trends is absent, limiting the ability to assess growth trajectory or consistency over time. The current snapshot provides a single-period view of financial performance.
Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The shares outstanding basic and diluted are identical at 91.31 million, suggesting no significant in-the-money options or convertible securities impacting dilution at the current market price.
Recent observations include analyst estimates with a mean price target of $18.67 and a mean recommendation of 1.67, indicating strong buy sentiment. News events reflect internal reconciler activities for analysis job admission rather than external corporate actions.
- The company holds a strong liquidity position with $37.07 million in cash and zero debt.
- Analyst sentiment is bullish with a mean price target of $18.67, significantly above the current market price of $5.99.
- Dilution risk is low with no difference between basic and diluted shares outstanding.
- Profitability signals are mixed with positive net income but negative return on equity and assets.
- EV/EBITDA is negative, suggesting operational cash flow challenges despite positive operating income.
- margin_outlook_rationale: Margins appear positive based on operating income but are obscured by negative return ratios.
Bull / Bear case
analysis pipelineIn focus — financials by report
Revenue $22.5M, +2,1% YoY; Operating income −511,6% YoY.
- ▍Revenue $22.5M, +2,1% YoY
- ▍Operating income −511,6% YoY
- ▍Net income −422,1% YoY
- ▍Free cash flow −371,7% YoY
- ▍Net margin -38.6%
Revenue $37.2M, +33,5% YoY; Operating income −80,2% YoY.
- ▍Revenue $37.2M, +33,5% YoY
- ▍Operating income −80,2% YoY
- ▍Net income −1 640,4% YoY
- ▍Free cash flow −364,9% YoY
- ▍Net margin -4.6%
Revenue $30.6M, +19,9% YoY; Operating income +63,6% YoY.
- ▍Revenue $30.6M, +19,9% YoY
- ▍Operating income +63,6% YoY
- ▍Net income +221,2% YoY
- ▍Free cash flow +126,6% YoY
- ▍Net margin 11.8%
Revenue $26.8M, +6,1% YoY; Operating income −33,5% YoY.
- ▍Revenue $26.8M, +6,1% YoY
- ▍Operating income −33,5% YoY
- ▍Net income −87,5% YoY
- ▍Free cash flow −41,5% YoY
- ▍Net margin 1.7%
Revenue $22.1M; Operating income $2.3M.
- ▍Revenue $22.1M
- ▍Operating income $2.3M
- ▍Net margin 12.2%
Revenue $27.9M; Operating income $597.0k.
- ▍Revenue $27.9M
- ▍Operating income $597.0k
- ▍Net margin -0.4%
Revenue $116.6M, +10,2% YoY; Operating income −28,9% YoY.
- ▍Revenue $116.6M, +10,2% YoY
- ▍Operating income −28,9% YoY
- ▍Net income −58,4% YoY
- ▍Free cash flow −35,5% YoY
- ▍Net margin 4.3%
Revenue $105.8M, −6,8% YoY; Operating income +124,0% YoY.
- ▍Revenue $105.8M, −6,8% YoY
- ▍Operating income +124,0% YoY
- ▍Net income +113,0% YoY
- ▍Free cash flow +117,5% YoY
- ▍Net margin 11.4%
Revenue $113.5M, +14 188,4% YoY; Operating income −697,4% YoY.
- ▍Revenue $113.5M, +14 188,4% YoY
- ▍Operating income −697,4% YoY
- ▍Net income −1 027,5% YoY
- ▍Free cash flow −75,3% YoY
- ▍Net margin -81.9%
Revenue $794.0k, −89,2% YoY; Operating income +90,4% YoY.
- ▍Revenue $794.0k, −89,2% YoY
- ▍Operating income +90,4% YoY
- ▍Net income +90,6% YoY
- ▍Free cash flow +40,0% YoY
- ▍Net margin -1038.0%
Revenue $7.3M; Operating income -$87.9M.
- ▍Revenue $7.3M
- ▍Operating income -$87.9M
- ▍Net margin -1198.3%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,45 |
| Revenue | —no estimate | —no estimate | 102,3M USD |
| Operating income | —no estimate | —no estimate | -19,0M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 3 000 @ $0,75exercise · 2026-06-18
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 2 800 @ $0,75exercise · 2026-06-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 5 000 @ $0,75exercise · 2026-06-10
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 6 418 @ $0,75exercise · 2026-06-10
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 14 500 @ $0,75exercise · 2026-06-09
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 3 000 @ $0,75exercise · 2026-06-09
- GC and Corporate Secretary · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $6,05grant · 2026-06-08
- Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 120 000 @ $6,05grant · 2026-06-08
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 15 401 @ $0,75exercise · 2026-06-05
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 19 575 @ $0,75exercise · 2026-06-04
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 4 000 @ $0,75exercise · 2026-05-26
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 3 500 @ $0,75exercise · 2026-05-22
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 12 820 @ $0,75exercise · 2026-05-21
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 9 400 @ $0,75exercise · 2026-05-20
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 9 120 @ $0,75exercise · 2026-05-19
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 200 @ $0,75exercise · 2026-05-18
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 13 100 @ $0,75exercise · 2026-05-15
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 15 580 @ $0,75exercise · 2026-05-14
- Director · Stock Option (Right to Buy) → Common StockDisposed 250 000 @ $10,18disposition · 2026-05-14
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Gyre Therapeutics, Inc. Market data — financials · 2026-07-29
- reconciler_enqueue (reconciler) on GYRE.O · 2026-07-29
- Gyre Therapeutics Inc Market data — analyst estimates · 2026-07-29
- Gyre Therapeutics Inc Market data — ESG · 2026-07-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Ying LuoPresident, Chief Executive Officer, Director
Insider activity
- Chief Operating Officer · Common StockSold 3 000 @ $6,35$19K · 2026-06-18
- Chief Operating Officer · Common StockOther 3 000 @ $0,75$2K · 2026-06-18
- Chief Operating Officer · Common StockOther 2 800 @ $0,75$2K · 2026-06-11
- Chief Operating Officer · Common StockSold 2 800 @ $6,17$17K · 2026-06-11
- Chief Operating Officer · Common StockOther 5 000 @ $0,75$4K · 2026-06-10
- Chief Operating Officer · Common StockSold 6 418 @ $6,21$40K · 2026-06-10
- Chief Operating Officer · Common StockSold 5 000 @ $6,24$31K · 2026-06-10
- Chief Operating Officer · Common StockOther 6 418 @ $0,75$5K · 2026-06-10
- Chief Operating Officer · Common StockOther 3 000 @ $0,75$2K · 2026-06-09
- Chief Operating Officer · Common StockSold 3 000 @ $6,15$18K · 2026-06-09
- Chief Operating Officer · Common StockOther 14 500 @ $0,75$11K · 2026-06-09
- Chief Operating Officer · Common StockSold 14 500 @ $6,14$89K · 2026-06-09
- Chief Operating Officer · Common StockOther 15 401 @ $0,75$12K · 2026-06-05
- Chief Operating Officer · Common StockSold 15 401 @ $6,40$99K · 2026-06-05
- Chief Operating Officer · Common StockOther 19 575 @ $0,75$15K · 2026-06-04
- Chief Operating Officer · Common StockSold 19 575 @ $6,13$120K · 2026-06-04
- Chief Operating Officer · Common StockOther 4 000 @ $0,75$3K · 2026-05-26
- Chief Operating Officer · Common StockSold 4 000 @ $6,10$24K · 2026-05-26
- Chief Operating Officer · Common StockSold 3 500 @ $6,08$21K · 2026-05-22
- Chief Operating Officer · Common StockOther 3 500 @ $0,75$3K · 2026-05-22
- Chief Operating Officer · Common StockSold 12 820 @ $6,15$79K · 2026-05-21
- Chief Operating Officer · Common StockOther 12 820 @ $0,75$10K · 2026-05-21
- Chief Operating Officer · Common StockOther 9 400 @ $0,75$7K · 2026-05-20
- Chief Operating Officer · Common StockSold 9 400 @ $6,15$58K · 2026-05-20
- Chief Operating Officer · Common StockOther 9 120 @ $0,75$7K · 2026-05-19
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Capex (annual): USD 1.19MUnknown
- Total operating expenses (annual): USD 105.1MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 0Unknown
- Cost of revenue (annual): USD 5.42MUnknown
- EPS (basic) (annual): USD-PER-SHARES 0Unknown
- R&D expense (annual): USD 13.7MUnknown
- Pre-tax income (annual): USD 14.44MUnknown
- Net income (annual): USD 9.88MUnknown
- Operating cash flow (annual): USD 1.01MUnknown
- Revenue (annual): USD 116.59MUnknown
- Total assets (annual): USD 166.13MUnknown
- Current liabilities (annual): USD 18.29MUnknown
- Total liabilities (annual): USD 23.85MUnknown
- Current assets (annual): USD 102.37MUnknown
- Operating income (annual): USD 11.49MUnknown
- Cash & equivalents (annual): USD 37.07MUnknown
- Shares outstanding (annual): 91.31MUnknown
- Shareholders' equity (annual): USD 106.03MUnknown
- Revenue (annual): USD 105.76MUnknown
- Cash & equivalents (annual): USD 11.81MUnknown
- R&D expense (annual): USD 12.02MUnknown
- Capex (annual): USD 2.31MUnknown
- Operating cash flow (annual): USD -3.64MUnknown
- Current assets (annual): USD 64.79MUnknown